Get the latest Anixa Biosciences Inc (ANIX) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment …Anixa Biosciences (ANIX) Quote Overview ... A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its annual earnings. In general, a lower number or multiple is usually ...Phone Number 6315495974. Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer ...Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer today announced that Cleveland Clinic presented the most up-to-date data from the ...In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), with a price target of $12.00. Yi Chen has given Anixa Biosciences ...SAN JOSE, Calif., Sept. 14, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases ...Anixa Biosciences Inc. Watch list NEW Set a price target alert Closed Last Updated: Nov 24, 2023 12:59 p.m. EST Delayed quote $ 2.9600 0.1000 3.50% Previous Close $2.8600 Advanced Charting... Phone Number 6315495974. Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer ...About Anixa Biosciences, Inc. Anixa is a publicly-traded biotechnology company developing a number of programs addressing cancer and infectious disease. Anixa's therapeutics portfolio includes a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology, and a …Anixa Biosciences Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.Track Anixa Biosciences Inc (ANIX) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsAbout Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine …18 Okt 2023 ... Anixa Biosciences; A Brief Investor Q&A With CEO and Chairman Amit Kumar, PhD. 3 views · 5 minutes ago ...more ...Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.Barcus covers the Healthcare sector, focusing on stocks such as Anixa Biosciences, uniQure, and Purple Biotech. According to TipRanks , Barcus has an average return of -0.9% and a 37.50% success ...Analyst's Opinion · Consensus Rating. Anixa Biosciences has received a consensus rating of Buy. · Price Target Upside/Downside. According to analysts' consensus ...In a report released today, Matthew Barcus from Chardan Capital reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), with a price target of $9.00.The company’s shares closed ...Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.Earnings for Anixa Biosciences are expected to decrease in the coming year, from ($0.32) to ($0.37) per share. Anixa Biosciences has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, January 3rd, 2024 based off prior year's report dates. Read More.Anixa Biosciences, Inc. Analyst Report: Moderna, Inc. Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA ... Anixa Biosciences, Inc. Stock technical analysis with dynamic chart and Real-time | BOERSE MUENCHEN: CY71 | BOERSE MUENCHEN 68.IWv0yX1ksJPFtk42eUQRWNQ-uhNUxqWNmPevcaQW8y4.RgairzcK2qGd4TsDDiJ3YYBc9yUTtc …Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.With a price/sales ratio of 433.5, ANIXA BIOSCIENCES INC has a higher such ratio than 99.07% of stocks in our set. Equity multiplier, or assets relative to ...According to 6 analyst offering 12-month price targets in the last 3 months, Anixa Biosciences has an average price target of $10.83 with a high of $12.00 and a low of $9.00.View ANIXA BIOSCIENCES INC ANIX investment & stock information. Get the latest ANIXA BIOSCIENCES INC ANIX detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Chardan Capital analyst Matthew Barcus maintained a Buy rating on Anixa Biosciences (ANIX – Research Report) today and set a price target of $9.00.The company’s shares opened today at $4.12 ...Anixa Biosciences plunges on upsizing stock offering to $22.5M SA News Tue, Mar. 23, 2021 2 Comments. Anixa Biosciences to raise $10M in bought deal offering SA News Mon, Mar. 22, 2021 1 Comment.Nov 21, 2023 · Get Anixa Biosciences Inc (ANIX.PH) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investments According to 6 analyst offering 12-month price targets in the last 3 months, Anixa Biosciences has an average price target of $11.0 with a high of $12.00 and a low of $9.00.Experienced scientist, investor and company builder. | Learn more about Amit Kumar's work experience, education, connections & more by visiting their ...Anixa Biosciences Announces Treatment of Second Patient in its Ovarian Cancer CAR-T Clinical Trial. SAN JOSE, Calif. , May 22, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in conjunction ... 6 months ago - PRNewsWire.Anixa Biosciences Stock Forecast. All Analysts Top Analysts Stock Price Forecast. According to 2 stock analysts, the average 12-month stock price forecast for ANIX stock stock is $10.5, which predicts an increase of 258.36%. The lowest target is $9.00 and the highest is $12. On average, analysts rate ANIX stock stock as a strong buy.SAN JOSE, Calif., Dec. 8, 2022 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...Anixa Biosciences (ANIX) In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences, with a price target of $12.00 . The company’s shares closed last ...Anixa Biosciences Inc stock performance at a glance. Check Anixa Biosciences Inc’s past financial performance, like revenue or net income, plus the top level summary of its …During the same time frame, the estimate for Anixa Biosciences’ 2024 loss per share has remained constant at 37 cents. Year to date, shares of ANIX have lost 32.2%.August 07, 2023. SAN JOSE, Calif., Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that its partner, Cleveland Clinic, has begun enrolling subjects in a treatment arm evaluating the combination of the ...SAN JOSE, Calif., Aug. 23, 2021 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, announced ...A high-level overview of Anixa Biosciences, Inc. (ANIX) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Mar 22, 2021 · Anixa Biosciences Announces $10 Million Bought Deal Offering of Common Stock. News provided by. Anixa Biosciences, Inc. 22 Mar, 2021, 17:18 ET. SAN JOSE, Calif., March 22, 2021 /PRNewswire ... Last Funding Type Grant; Also Known As ITUS Corporation; Legal Name CopyTele, Inc. Stock Symbol NASDAQ:ANIX; Company Type For Profit. Phone Number 6315495974.SAN JOSE, Calif., April 28, 2022 /PRNewswire/ --Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today ...SAN JOSE, Calif., Aug. 7, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today ...Anixa Biosciences Inc stock performance at a glance. Check Anixa Biosciences Inc’s past financial performance, like revenue or net income, plus the top level summary of its …Apr 18, 2023 · In a report released today, Matthew Barcus from Chardan Capital reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), with a price target of $9.00.The company’s shares closed ... In July 2023, Anixa Biosciences had US$26m in cash, and was debt-free. In the last year, its cash burn was US$5.8m. That means it had a cash runway of about 4.4 years as of July 2023.Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. You may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a broker to begin trading.Company to present on its ongoing Phase 1 ovarian cancer CAR-T trial. SAN JOSE, Calif., Oct. 31, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it will present at the Ovarian Cancer National Conference taking place from November 1 – 3, 2023.Discover historical prices for ANIX stock on Yahoo Finance. View daily, weekly or monthly format back to when Anixa Biosciences, Inc. stock was issued. 15 Agu 2022 ... PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa") a biotechnology company focused on the treatment and prevention of cancer ...SAN JOSE, Calif., May 22, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that, in ...Anixa Biosciences, Inc. announced that, in partnership with Moffitt Cancer Center, it has completed treatment of the first patient cohort in the ongoing clinical trial of …. 14 Agu 2023 ... SAN JOSE, Calif., Aug. 14, 2023 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company ...Anixa Biosciences Inc stocks price quote with latest real-time prices, charts, financials, latest news, technical analysis and opinions.Anixa Biosciences, Inc. Stock price Equities ANIX US03528H1095 Biotechnology & Medical Research Summary Quotes Charts News Ratings Calendar Company Financials …Stock Information. Quote; Charts; Historical Data; Analyst Coverage. ... Anixa Biosciences Appoints Accomplished Medical Oncologist and Biotechnology Executive, Dr ...Stock analysis for Anixa Biosciences Inc (ITUS:US) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Complete Anixa Biosciences Inc. stock information by Barron's. View real-time ANIX stock price and news, along with industry-best analysis.Nov 29, 2023 · The Anixa Biosciences Inc. stock price fell by -0.90% on the last day (Wednesday, 29th Nov 2023) from $3.34 to $3.31. During the last trading day the stock fluctuated 5.92% from a day low at $3.20 to a day high of $3.39. The price has risen in 6 of the last 10 days and is up by 15.73% over the past 2 weeks. H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report) today and set a price target of $11.00. The company’s shares closed yesterday at $4.21.Penny stocks may sound like an interesting investment option, but there are some things that you should consider before deciding whether this is the right investment choice for you.Get Anixa Biosciences Inc (ANIX.PH) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsAbout Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutic portfolio consists of an ovarian cancer immunotherapy program being developed in collaboration with Moffitt Cancer Center, which uses a novel type of CAR-T, known as chimeric endocrine …The latest price target for Anixa Biosciences ( NASDAQ: ANIX) was reported by HC Wainwright & Co. on Tuesday, August 29, 2023. The analyst firm set a price target for 12.00 expecting ANIX to rise ...Stock Price Forecast. According to 2 stock analysts, the average 12-month stock price forecast for ANIX stock stock is $10.5, which predicts an increase of 210.65%. The lowest target is $9.00 and the highest is $12. On average, analysts rate ANIX stock stock as a strong buy.Nov 24, 2023 · Anixa Biosciences (ANIX) Quote Overview ... A stock with a P/E ratio of 20, for example, is said to be trading at 20 times its annual earnings. In general, a lower number or multiple is usually ... Complete Anixa Biosciences Inc. stock information by Barron's. View real-time ANIX stock price and news, along with industry-best analysis.Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that the U.S. Patent and ...We sorted the Argus stock universe for companies with a BUY rating, a market cap over $8 billion, and the highest financial strength ratings. ... Anixa Biosciences, Inc. ("Anixa" or the "Company ...Anixa Biosciences plunges on upsizing stock offering to $22.5M SA News Tue, Mar. 23, 2021 2 Comments. Anixa Biosciences to raise $10M in bought deal offering SA News Mon, Mar. 22, 2021 1 Comment.Some better-ranked stocks worth mentioning are Ligand Pharmaceuticals LGND, Acadia Pharmaceuticals ACAD and Anixa Biosciences ANIX. While LGND sports a Zacks Rank #1 (Strong Buy), ACAD and ANIX ...Anixa Biosciences - ANIX - Stock Price Today - Zacks Anixa Biosciences (ANIX) (Delayed Data from NSDQ) $3.34 USD +0.03 (0.91%) Updated Nov 30, 2023 04:00 PM ET After-Market: $3.34 0.00...Anixa Biosciences (Nasdaq:ANIX) - Stock Price, News & Analysis - Simply Wall St Stocks / Pharmaceuticals & Biotech Anixa Biosciences NasdaqCM:ANIX …We sorted the Argus stock universe for companies with a BUY rating, a market cap over $8 billion, and the highest financial strength ratings. ... Anixa Biosciences, Inc. ("Anixa" or the "Company ... Overview. Anixa is a biotechnology company focused on the treatment and prevention of cancer. Anixa's therapeutics portfolio consists of a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. Anixa’s vaccine portfolio consists of technology focused on the immunization ...The cell therapy being evaluated in Anixa's Phase 1 study differs from traditional CAR-T therapy in that it targets the FSHR, which research indicates is exclusively expressed on ovarian cells in healthy adult females. About Anixa Biosciences, Inc. Anixa is a clinical-stage biotechnology company focused on the treatment and prevention of …Amit Kumar. https://www.anixa.com. Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell ...View ANIX Stock Real Time Quote, Anixa Biosciences, Inc stock price with interactive chart, get the latest alerts for Anixa Biosciences, Inc, with indicator levels, dividend and earnings details. Add a live free portfolio.ANIXA BIOSCIENCES INC (ANIX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is…SAN JOSE, Calif., April 28, 2022 /PRNewswire/ --Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining the design of its breast cancer vaccine trial at the American Society of Clinical Oncology (ASCO) Annual …Sep 28, 2018 · SAN JOSE, Calif., Sept. 28, 2018 /PRNewswire/ -- ITUS Corporation (the "Company") (NASDAQ: ITUS ), a biotechnology company focused on using the body's immune system to fight cancer, today ... Anixa Biosciences, Inc. Common Stock (ANIX) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets.Last Funding Type Grant; Also Known As ITUS Corporation; Legal Name CopyTele, Inc. Stock Symbol NASDAQ:ANIX; Company Type For Profit. Phone Number 6315495974.The estimated net worth of Amit Kumar is at least $1.51 million as of July 31st, 2023. Dr. Kumar owns 461,925 shares of Anixa Biosciences stock worth more than $1,510,495 as of October 18th. This net worth approximation does not reflect any other investments that Dr. Kumar may own. Additionally, Dr. Kumar receives an annual salary …Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that the Canadian Intellectual ...Anixa Biosciences Inc: Overview. Anixa Biosciences Inc (Anixa) is a biotechnology company. The company develops and acquires patented technologies in the areas such as cancer diagnostics, encrypted communications and semiconductor fabrication. It also develops non-invasive blood tests for the early detection of solid tumor-based cancers.Anixa Biosciences, Inc. is a biotechnology company. The Company is primarily engaged in developing vaccines and therapies that are focused on critical unmet needs in oncology and infectious disease. The Company's segments include CAR-T Therapeutics, Cancer Vaccines, Anti-Viral Therapeutics and Others.According to 6 analyst offering 12-month price targets in the last 3 months, Anixa Biosciences has an average price target of $11.0 with a high of $12.00 and a low of $9.00.Anixa Biosciences Inc. company facts, information and financial ratios from MarketWatch. ... 9:34a Target stock price target raised to $160 from $135 at BofA SecuritiesAnixa Biosciences Inc. company facts, information and financial ratios from MarketWatch. ... 9:34a Target stock price target raised to $160 from $135 at BofA SecuritiesAmit Kumar. https://www.anixa.com. Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company’s therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell ...Anixa Biosciences - ANIX - Stock Price Today - Zacks Anixa Biosciences (ANIX) (Delayed Data from NSDQ) $3.34 USD +0.03 (0.91%) Updated Nov 30, 2023 04:00 PM ET After-Market: $3.34 0.00...SAN JOSE, Calif., April 28, 2022 /PRNewswire/ --Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced a presentation outlining the design of its breast cancer vaccine trial at the American Society of Clinical Oncology (ASCO) Annual …